Non-small Cell Lung Cancer(NSCLC) Clinical Trial
Official title:
To Compare the Efficacy and Safety of BP102 in Combination With Paclitaxel/Carboplatin and Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC - a Randomized, Double-blind, Positive Parallel Control, Multicentre Phase III Clinical Trial
This is a randomized, double-blind, positive parallel control, multicentre Phase III clinical trial, a clinical trial of biosimilar drugs, so the type of comparison is equivalence test.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01712217 -
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06332755 -
Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors
|
Phase 1 | |
Recruiting |
NCT02820116 -
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
|
Phase 2 | |
Active, not recruiting |
NCT02667743 -
Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC
|
Phase 3 | |
Recruiting |
NCT02036359 -
Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca
|
Phase 2 | |
Not yet recruiting |
NCT05765877 -
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT02603003 -
the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs
|
Phase 1 | |
Active, not recruiting |
NCT01637597 -
Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation
|
N/A |